Oesophageal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with head and neck cancer, non-small cell lung cancer, or another type of solid tumour, and are being treated to manage the disease (not to cure it), or in some cases receiving treatment after surgery for lung cancer
- Your doctor has recommended a type of immunotherapy drug called a PD-1 or PD-L1 inhibitor as part of your standard care
- You may or may not have had radiation treatment to one or more areas where the cancer has spread
- You are at least 18 years old (there is no upper age limit)
- Both men and women are welcome to participate
Who may not be able to join:
- You have been diagnosed with melanoma (a type of skin cancer)
- You are able to have children but are not willing to use effective contraception during the study treatment
- You are currently struggling with ongoing drug or alcohol misuse
- You are not able or willing to follow the rules and schedule set out by the study
- You are currently living in a care facility (confirm with trial site)
- You are not able to speak German
- You are currently imprisoned or detained under a legal or government order
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Markus Hecht, PD Dr., Universitätsklinikum Erlangen, Department of Radiation Oncology
Phone: +49 9131 85
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overallsurvival; Longitudinal Immunophenotype; Predictors in pattern recognition analyses; Immune-associated side effects
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.